Get the Stockscreener App
2.41
2.03%
-0.05
Onkure Therapeutics Inc stock is traded at $2.41, with a volume of 19,895.
It is down -2.03% in the last 24 hours and down -24.92% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.
See More
Previous Close:
$2.46
Open:
$2.4528
24h Volume:
19,895
Relative Volume:
0.17
Market Cap:
$32.65M
Revenue:
-
Net Income/Loss:
$-81.21M
P/E Ratio:
-0.3908
EPS:
-6.1668
Net Cash Flow:
$-61.42M
1W Performance:
+3.88%
1M Performance:
-24.92%
6M Performance:
+20.50%
1Y Performance:
-55.78%
1-Day Range:
$2.3501
$2.4528
1-Week Range:
$2.30
$2.5899
52-Week Range:
$1.70
$6.176
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.41 | 33.33M | 0 | -81.21M | -61.42M | -6.1668 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
EV Market: Should I set a stop loss on OnKure Therapeutics Inc2025 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
Published on: 2026-01-29 15:39:37 - mfd.ru
Why OnKure Therapeutics Inc. stock could be next big winnerShort Interest Overview & High Yield Trading Alerts - bollywoodhelpline.com
Analyzing Nautilus Biotechnology (NASDAQ:NAUT) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Rating of “Hold” from Analysts - Defense World
Published on: 2026-01-11 10:53:08 - Улправда
Targets Report: How risky is OnKure Therapeutics Inc stock nowEarnings Recap Summary & Weekly Sector Rotation Insights - Bộ Nội Vụ
How OnKure Therapeutics Inc. stock performs in weak economyEarnings Overview Report & Daily Market Momentum Tracking - Улправда
Geopolitics Watch: How risky is OnKure Therapeutics Inc. stock nowMarket Sentiment Review & Detailed Earnings Play Strategies - Улправда
Bear Alert: Will OnKure Therapeutics Inc stock attract ESG investorsFed Meeting & Weekly High Momentum Picks - Bộ Nội Vụ
Rally Mode: Why OnKure Therapeutics Inc. stock could be next big winnerJuly 2025 Snapshot & Safe Entry Trade Reports - Улправда
How OnKure Therapeutics Inc. stock performs after earnings - ulpravda.ru
What hedge fund activity signals for OnKure Therapeutics Inc. stock2026 world cup usa national team quarterfinals key players high defensive line odds analysis insights - ulpravda.ru
Will OnKure Therapeutics Inc. stock attract more institutional investors2026 world cup usa national team third place match playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Quarterly Recap: How British Land Company PLC BLD stock expands through international marketsFed Meeting & AI Forecasted Entry and Exit Points - moha.gov.vn
Bull Bear: Why OnKure Therapeutics Inc stock is a must watch in 2025Weekly Profit Report & Low Risk Entry Point Tips - moha.gov.vn
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 25.6% in December - Defense World
OnKure Therapeutics CEO Saccomano sells $258 in stock By Investing.com - Investing.com India
OnKure Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Identify Winning Stocks - earlytimes.in
OnKure Therapeutics CFO Leverone sells $896 in stock By Investing.com - Investing.com Canada
OnKure Therapeutics CFO Leverone sells $896 in stock - Investing.com
OnKure Therapeutics CEO Saccomano sells $258 in stock - Investing.com
Is OnKure Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Trade Execution Alerts - Улправда
Aug Technicals: What analyst consensus says on UYSCU stockJuly 2025 Macro Moves & Safe Entry Trade Reports - moha.gov.vn
Can OnKure Therapeutics Inc. stock sustain free cash flow growthWeekly Stock Recap & Precise Swing Trade Alerts - Улправда
Can OnKure Therapeutics Inc. stock rebound after recent weaknessWeekly Market Outlook & Free Community Consensus Stock Picks - Улправда
Why OnKure Therapeutics Inc. stock could rally in 2025Wall Street Watch & Weekly High Conviction Trade Ideas - Bölüm Sonu Canavarı
Why OnKure Therapeutics Inc. stock is considered a top pick2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
Why OnKure Therapeutics Inc. stock is a must watch in 2025July 2025 Outlook & AI Forecasted Stock Moves - DonanımHaber
CEO Change: How OnKure Therapeutics Inc. stock performs in high volatility marketsMarket Volume Report & Capital Protection Trade Alerts - Улправда
Aug PostEarnings: Why OnKure Therapeutics Inc. stock is considered a top pickJuly 2025 Market Mood & Risk Managed Investment Signals - Улправда
Is OnKure Therapeutics Inc. stock a buy on dipsMarket Risk Summary & Accurate Intraday Trade Tips - Улправда
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) dropped from NASDAQ Biotechnology Index - marketscreener.com
OnKure Therapeutics Earnings Notes - Trefis
Acorn Capital Advisors LLC Grows Position in OnKure Therapeutics, Inc. $OKUR - Defense World
Why OnKure Therapeutics Inc stock could rally in 2025Weekly Volume Report & Reliable Entry Point Trade Alerts - moha.gov.vn
Ready to Jump After Recent Trade: OnKure Therapeutics Inc (OKUR) - Setenews
Why OnKure Therapeutics Inc. stock could outperform in 2025CPI Data & Weekly Breakout Stock Alerts - Newser
OnKure Therapeutics (OKUR) Stock Analysis Report | Financials & Insights - Benzinga
Will OnKure Therapeutics Inc. stock sustain high P E ratiosMarket Performance Recap & Capital Efficient Trade Techniques - Newser
Published on: 2025-11-27 20:24:24 - BỘ NỘI VỤ
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
[424B3] OnKure Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
What margin trends mean for OnKure Therapeutics Inc. stockGDP Growth & Weekly Chart Analysis and Guides - newser.com
Why OnKure Therapeutics Inc. stock is a value investor pickJuly 2025 Trends & Short-Term Swing Trade Alerts - newser.com
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):